STAT3 and carcinoma: Recently, Debio 0617B is the first-in-class kinase inhibitor that targeting phospho-STAT3 (pSTAT3) and/or pSTAT5 specifically in carcinomas by suppressing the activity of JAK, SRC, ABL, and class III/V receptor tyrosine kinases (RTK).